Global Markets Direct’s, 'Neuralgia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neuralgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuralgia. Neuralgia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Neuralgia. - A review of the Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Neuralgia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Neuralgia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Neuralgia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Neuralgia - Pipeline Review, H1 2013 Table of Contents
Table of Contents 2 Introduction 7 Neuralgia Overview 8 Therapeutics Development 9 Neuralgia Therapeutics under Development by Companies 11 Neuralgia Therapeutics under Investigation by Universities/Institutes 20 Late Stage Products 22 Mid Clinical Stage Products 23 Early Clinical Stage Products 24 Discovery and Pre-Clinical Stage Products 25 Neuralgia Therapeutics - Products under Development by Companies 26 Neuralgia Therapeutics - Products under Investigation by Universities/Institutes 38 Companies Involved in Neuralgia Therapeutics Development 39 Neuralgia - Therapeutics Assessment 135 Drug Profiles 143 Neuralgia Therapeutics - Drug Profile Updates 377 Neuralgia Therapeutics - Discontinued Products 430 Neuralgia Therapeutics - Dormant Products 436 Neuralgia - Product Development Milestones 445 Appendix 452
Number of Products under Development for Neuralgia, H1 2013 29 Products under Development for Neuralgia - Comparative Analysis, H1 2013 30 Products under Development by Companies, H1 2013 31 Products under Investigation by Universities/Institutes, H1 2013 40 Late Stage Products, H1 2013 42 Mid Clinical Stage Products, H1 2013 43 Early Clinical Stage Products, H1 2013 44 Discovery and Pre-Clinical Stage Products, H1 2013 45 Assessment by Monotherapy Products, H1 2013 155 Assessment by Combination Products, H1 2013 156 Assessment by Route of Administration, H1 2013 157 Assessment by Stage and Route of Administration, H1 2013 158 Assessment by Molecule Type, H1 2013 160 Assessment by Stage and Molecule Type, H1 2013 161